Silk Biomed SL (Silk) ha compartido esto
🚀 Driving Innovation with EIC Pathfinder Grant! We are thrilled to announce that our project, ISOS, has been awarded by the European Commission under grant agreement No. 101130454! 🎉 ISOS Project EU aims to revolutionise chronic disease treatment by developing the first biomedical product capable of in-situ fabrication and auto-renewed delivery of therapeutic compounds. Using complex ecosystems of genetically engineered bacteria within a biomaterial-based bioreactor, ISOS will produce therapeutic molecules "on demand", responding directly to the patient's pathological environment. This innovative approach will personalise treatment for conditions like age-related macular degeneration, potentially replacing repeated intraocular injections with a single implantable bioreactor. This groundbreaking project could pave the way for a new generation of therapeutic products, offering personalised treatments with rigorous control of drug production and delivery. We look forward to working with our incredible consortium partners (Silk Biomed SL (Silk), Universidad Complutense de Madrid, Leipzig University, Fraunhofer IZI, Alien Technology Transfer, Northumbria University) to drive this innovation and make a lasting impact on healthcare! 🌍 🔬 💡 🔗 Learn more about the project by visiting our ISOS website, and follow us on LinkedIn and X. https://lnkd.in/eaKgVRQj #EuropeanCommission #EUFunding #HorizonEurope #EIC #PathFinder #ResearchAndInnovation #ISOS #Innovation #BiomedicalResearch #ChronicDiseaseTreatment